Neumora Therapeutics, Inc. Common Stock (NMRA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -46.4M | -47.95M | -46.63M | -52.4M | -59.45M | -50.34M | -33.48M | -56.16M | -42.95M | -51.44M | -47.77M | -31.02M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 21.94% | 4.74% | -39.27% | 6.68% | -38.4% | 2.14% | 29.91% | -81.03% | -30.01% | -69.41% | - | -16.71% |
| Net Income | -53.46M | -59.45M | -56.76M | -52.73M | -67.99M | -58.82M | -72.55M | -58.7M | -53.72M | -108.73M | -53.03M | -38.54M |
| Depreciation & Amortization | 8K | 9K | 23K | 19K | 157K | 157K | 156K | 160K | 158K | 166K | 173K | 991K |
| Stock-Based Compensation | 7.41M | 7.41M | 5.98M | 7.17M | 9.32M | 9.9M | 9.95M | 12.77M | 7.37M | 6.05M | 6.45M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 406K | 870K | -364K | 747K | -412K | -225K | -472K | -1.35M | -356K | 64.18M | -177K | 1.43M |
| Working Capital Changes | -765K | 3.21M | 4.48M | -7.6M | -525K | -1.36M | 29.43M | -9.03M | 3.59M | -13.11M | -1.19M | 5.1M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.68M | 2.83M | -96K | -408K | -2.25M | -2.9M | 5.03M | -410K | 1.16M | -1.91M | 306K | 7.04M |
| Cash from Investing | 71K | 42.65M | 51.32M | 30.4M | 44.16M | -98.8M | 156.99M | 21.25M | -150M | 13.68M | 23.82M | 24.08M |
| Capital Expenditures | 0 | 16K | 0 | 0 | 0 | 0 | 0 | 0 | -775K | -4.63M | -37K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 71K | 0 | 0 | 84K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 184K | 71K | 896K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 10.88M | 58.77M | -136K | 18.46M | 0 | 15.57M | 1.53M | 2.65M | 1.84M | -481K | 232.02M | 292K |
| Debt Issued (Net) | 0 | 38.9M | -136K | 18.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 10.88M | 216K | 0 | 59K | 0 | 13.69M | 0 | 2.65M | 1.84M | -481K | 0 | 292K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 19.65M | 0 | 0 | 0 | 1.88M | 1.53M | 0 | 0 | 0 | 232.02M | 0 |
| Net Change in Cash | -35.46M | 53.46M | 4.55M | -3.55M | -15.29M | -133.57M | 125.04M | -32.25M | -191.11M | -38.25M | 208.07M | -6.65M |
| Free Cash Flow | -46.4M | -47.94M | -46.65M | -52.4M | -59.45M | -50.34M | -33.48M | -56.16M | -42.95M | -51.49M | -47.81M | -31.02M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 21.94% | 4.77% | -39.32% | 6.68% | -38.4% | 2.23% | 29.97% | -81.03% | -29.86% | -69.42% | - | -15.92% |
| FCF per Share | -0.26 | -0.29 | -0.29 | -0.32 | -0.37 | -0.31 | -0.21 | -0.35 | -0.27 | -0.32 | -0.31 | -0.20 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.81x | 0.82x | 0.99x | 0.87x | 0.86x | 0.46x | 0.96x | 0.80x | 0.47x | 0.90x | 0.80x |
| Interest Paid | 0 | 833K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 323K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |